JTT-662

About Akros Pharma

Akros Pharma is a clinical-stage biotechnology company serving as the US development arm of Shionogi. Its pipeline consists of seven small molecule drug candidates, primarily in Phase 1 and Phase 2 trials, targeting autoimmune diseases, type 2 diabetes, chronic heart failure, neurodegenerative diseases, pulmonary arterial hypertension, and peripheral artery disease. The company leverages Shionogi's discovery engine and is led by a management team with deep expertise in clinical development, regulatory affairs, and intellectual property. As a private, subsidiary entity, its financial position and strategic direction are intrinsically linked to its parent company.

Therapeutic Areas

Other Type 2 diabetes mellitus Drugs